Browse > Article
http://dx.doi.org/10.5352/JLS.2011.21.11.1549

Enhancement of TRAIL-Mediated Apoptosis by Genistein in Human Hepatocellular Carcinoma Hep3B Cells: Roles of p38 MAPK Signaling Pathway  

Jin, Cheng-Yun (Department of Biomaterial Control (BK21 program) and Blue-Bio Industry Regional Innovation Center, Dongeui University)
Park, Cheol (Medical Research Institute, Chungbuk National University College of Medicine)
Park, Sang-Eun (Department of Internal Oriental Medicine, Dongeui University College of Oriental Medicine)
Hong, Sang-Hoon (Department of Internal Oriental Medicine, Dongeui University College of Oriental Medicine)
Choi, Yung-Hyun (Department of Biomaterial Control (BK21 program) and Blue-Bio Industry Regional Innovation Center, Dongeui University)
Publication Information
Journal of Life Science / v.21, no.11, 2011 , pp. 1549-1557 More about this Journal
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in many types of transformed cells; however, some human hepatocellular carcinoma cells are particularly resistant to the effects of TRAIL. Although genistein, a natural isoflavonoid phytoestrogen, has been shown to have pro-apoptotic activity against human cancer cell lines, little is known about the mechanism of genistein in terms of TRAIL-induced apoptosis. In the present study, it was investigated whether or not combined treatment with genistein and TRAIL synergistically induced apoptosis in Hep3B hepatocarcinoma cells. Results indicate that treatment with TRAIL in combination with nontoxic concentrations of genistein sensitized TRAIL-resistant Hep3B cells to TRAIL-induced apoptosis, which was associated with mitochondrial dysfunction. Further, the inhibition of p38 mitogen-activated protein kinase (MAPK) activation markedly decreased genistein and TRAIL-induced cell viability and apoptosis by enhanced truncation of Bid, increase of pro-apoptotic Bax, decrease of anti-apoptotic Bcl-2, and release of cytochrome c from mitochondria to cytoplasm. Activation of caspases and degradation of poly (ADP-ribose) polymerase induced by the combined treatment was also markedly increased by the inhibition of p38 MAPK, through the mitochondrial amplification step. In conclusion, our data suggest that genistein sensitizes TRAIL-induced-apoptosis via p38 MAPK-dependent pathway.
Keywords
TRAIL; genistein; apoptosis; p38 MAPK;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jin, C. Y., C. Park, J. Cheong, B. T. Choi, T. H. Lee, J. D. Lee, W. H. Lee, G. Y. Kim, C. H. Ryu, and Y. H. Choi. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257, 56-64.   DOI   ScienceOn
2 Jin, C. Y., C. Park, G. Y. Kim, S. J. Lee, W. J. Kim, and Y. H. Choi. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem. Biol. Interact. 180, 143-150.   DOI   ScienceOn
3 Jin, C. Y., C. Park, S. K. Moon, G. Y. Kim, T. K. Kwon, S. J. Lee, W. J. Kim, and Y. H. Choi. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20, 713-722.   DOI   ScienceOn
4 Kang, J. L., H. W. Lee, H. J. Kim, H. S. Lee, V. Castranova, C. M. Lim, and Y. Koh. 2005. Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-$\kappa$B, and serine and tyrosine phosphorylation of $I{\kappa}B-\alpha$ in lipopolysaccharide- stimulated raw 264.7 macrophages. J. Toxicol. Environ. Health 68, 1643-1662.   DOI   ScienceOn
5 Kim, H., E. H. Kim, Y. W. Eom, W. H. Kim, T. K. Kwon, S. J. Lee, and K. S. Choi. 2006. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 66, 1740-1750.   DOI   ScienceOn
6 Abdollahi, T. 2004. Potential for TRAIL as a therapeutic agent in ovarian cancer. Vitam. Horm. 67, 347-364.   DOI
7 Abdollahi, T., N. M. Robertson, A. Abdollahi, and G. Litwack. 2005. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis 10, 1383-1393.   DOI   ScienceOn
8 Van Geelen, C. M., E. G. de Vries, and S. de Jong. 2004. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7, 345-358.   DOI   ScienceOn
9 Wang, C., T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling. 2009. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1- JNK/p38 and inhibiting $I{\kappa}B{\alpha}$ kinase-NF$\kappa$B. J. Biol. Chem. 284, 3804-3813.   DOI
10 Weldon, C. B., A. P. Parker, D. Patten, S. Elliott, Y. Tang, D. E. Frigo, C. M. Dugan, E. L. Coakley, N. N. Butler, J. L. Clayton, J. Alam, T. J. Curiel, B. S. Beckman, B. M. Jaffe, and M. E. Burow. 2004. Sensitization of apoptotically- resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int. J. Oncol. 24, 1473-1480.
11 Yamanaka, T., K. Shiraki, K. Sugimoto, T. Ito, K. Fujikawa, M. Ito, K. Takase, M. Moriyama, T. Nakano, and A. Suzuki. 2000. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32, 482-490.   DOI   ScienceOn
12 Pei, Z., L. Chu, W. Zou, Z. Zhang, S. Qiu, R. Qi, J. Gu, C. Qian, and X. Liu. 2004. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371-1381.   DOI   ScienceOn
13 Zauli, G., E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero. 2004. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104, 2044-2050.   DOI   ScienceOn
14 Lub-de Hooge, M. N., S. de Jong, C. Vermot-Desroches, J. E. Tulleken, E. G. de Vries, and J. G. Zijlstra. 2004. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis- inducing ligand level mediated by the p38 mitogen- activated protein kinase signaling pathway. Shock 22, 186-188.   DOI   ScienceOn
15 Park, J. H., E. J. Oh, Y. H. Choi, C. D. Kang, H. S. Kang, D. K. Kim, K. I. Kang, and M. A. Yoo. 2001. Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. Int. J. Oncol. 18, 997-1002.
16 Pinski, J., Q. Wang, M. L. Quek, A. Cole, J. Cooc, K. Danenberg, and P. V. Danenberg. 2006. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66, 1136-1143.   DOI   ScienceOn
17 Raffoul, J. J., Y. Wang, O. Kucuk, J. D. Forman, F. H. Sarkar, and G. G. Hillman. 2006. Genistein inhibits radiation-induced activation of NF-$\kappa$B in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6, 107.   DOI
18 Shankar, S, and R. Srivastava. 2004. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7, 139-156.   DOI   ScienceOn
19 Ravindranath, M. H., S. Muthugounder, N. Presser, and S. Viswanathan. 2004. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 546, 121-165.   DOI
20 Sarkar, F. H., S. Adsule, S. Padhye, S. Kulkarni, and Y. Li. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 6, 401-407.   DOI   ScienceOn
21 Srivastava, R. K. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3, 535-546.   DOI   ScienceOn
22 Kim, S. H., S. H. Kim, S. C. Lee, and Y. S. Song. 2009. Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells. Ann. N Y Acad. Sci. 1171, 196-201.   DOI   ScienceOn
23 Kim, Y. H., J. W. Park, J. Y. Lee, and T. K. Kwon. 2004. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25, 1813-1820.   DOI
24 Kim, Y. S., R. F. Schwabe, T. Qian, J. J. Lemasters, and D. A. Brenner. 2002. TRAIL-mediated apoptosis requires NF-$\kappa$ B inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36, 1498-1508.
25 Kischkel, F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim, and A. Ashkenazi. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620.   DOI   ScienceOn
26 Lee, M. W., J. H. Bach, H. J. Lee, D. Y. Lee, W. S. Joo, Y. S. Kim, S. C. Park, K. Y. Kim, W. B. Lee, and S. S. Kim. 2005. The activation of ERK1/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells. Cancer Invest 23, 586-592.   DOI   ScienceOn
27 Lamy, V., S. Bousserouel, F. Gosse, C. Minker, A. Lobstein, and F. Raul. 2011. Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Oncol. Rep. 26, 109-114.
28 LeBlanc, H., D. Lawrence, E. Varfrolomeev, K. Totpal, J. Morlan, P. Schow, S. Fong, R. Schwall, D. Sinicropi, and A. Ashkenazi. 2002. Tumor-cell resistance to death receptor- induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8, 274-281.   DOI   ScienceOn
29 Lee, J., J. S. Shin, J. Y. Park, D. Kwon, S. J. Choi, S. J. Kim, and I. H. Choi. 2003. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis- inducing ligand induced by interferon-gamma in fetal brain astrocytes. J. Neurosci. Res. 74, 884-890.   DOI   ScienceOn
30 Gonzalez-Guerrico, A. M. and M. G. Kazanietz. 2005. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J. Biol. Chem. 280, 38982-38991.   DOI
31 Guicciardi, M. E., S. F. Bronk, N. W. Werneburg, and G. J. Gores. 2007. cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am. J. Physiol. Gastrointest Liver Physiol. 292, 1337-1346.   DOI
32 Hao, C., J. H. Song, B. His, J. Lewis, D. K. Song, K. C. Petruk, D. L. Tyrrell, and N. M. Kneteman. 2004. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64, 8502-8506.   DOI   ScienceOn
33 Choi, Y. H., W. H. Lee, K. Y. Park, and L. Zhang. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91, 164-173.   DOI
34 Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R. H. Schwall. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.   DOI   ScienceOn
35 Chawla-Sarker, M., S. I. Bae, F. J. Reu, B. S. Jacobs, D. J. Lindner, and E. C. Borden. 2004. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11, 915-923.   DOI   ScienceOn
36 Choi, K., S. Song, and C. Choi. 2008. Requirement of caspases and p38 MAPK for TRAIL-mediated ICAM-1 expression by human astroglial cells. Immunol. Lett. 117, 168-173.   DOI   ScienceOn
37 Choi, Y. H., L. Zhang, W. H. Lee, and K. Y. Park. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13, 391-396.
38 Cohen, J. H., A. R. Kristal, and J. L. Stanford. 2000. Fruit and vegetable intakes and prostate cancer risk. J. Natl. Cancer Inst. 5, 61-68.
39 Conklin, C. M., J. F. Bechberger, D. McFabe, N. Guthrie, E. M. Kurowska, and C. C. Naus. 2007. Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28, 93-100.   DOI   ScienceOn